Evidence map›Paper›PMID 35250310›Full record

ArticleCancer management and research2022

Resource Oriented Decision Making for Treatment of Metastatic Colorectal Cancer (mCRC) in a Lower-Middle Income Country: Egyptian Foundation of Medical Sciences (EFMS) Consensus Recommendations 2020.

Noha Rashad, Mohamed Abdulla, Mohamed Farouk, Yasser Elkerm, Salem Eid Salem, Maha Yahia, Amr S Saad, Ahmed Hassan Abdel Aziz, Ghada Refaat, Ibrahim Awad and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. The CAIRO Journal Club: A Decade of Impact.Journal of cancer education : the official journal of the American Association for Cancer Education · 2025
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 9 institutions in 4 countries.

Noha RashadMedical Oncology Department, Faculty of Medicine, Suez University, Suez, Egypt.ORCID 0000-0002-3684-9271
Mohamed AbdullaClinical Oncology and Nuclear Medicine Department, Kasr Al-Aini Medical School, Cairo University, Cairo, Egypt.
Mohamed FaroukDepartment of Clinical Oncology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Yasser ElkermDepartment of Cancer Management and Research, Medical Research Institute Hospital, University of Alexandria, Alexandria, Egypt.
Salem Eid SalemDepartment of Medical Oncology, National Cancer Institute (NCI), Cairo University, Cairo, Egypt.ORCID 0000-0002-6204-5031
Maha YahiaDepartment of Medical Oncology, National Cancer Institute (NCI), Cairo University, Cairo, Egypt.
Amr S SaadClinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Ahmed Hassan Abdel AzizClinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Ghada RefaatClinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Ibrahim AwadDepartment of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Maha ElNaggarClinical Oncology Department, Assiut University Hospital, Assiut, Egypt.
Khaled KamalClinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.ORCID 0000-0001-7096-5674
Basel RefkyDepartment of Surgical Oncology, Oncology Center Mansoura University, Mansoura, Egypt.
Mohamed AbdelkhalekDepartment of Surgical Oncology, Oncology Center Mansoura University, Mansoura, Egypt.ORCID 0000-0002-2225-500X
Ahmed TounyDepartment of Surgical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt.
Loay KassemClinical Oncology and Nuclear Medicine Department, Kasr Al-Aini Medical School, Cairo University, Cairo, Egypt.ORCID 0000-0001-6559-5867
Emad ShashDepartment of Medical Oncology, National Cancer Institute (NCI), Cairo University, Cairo, Egypt.ORCID 0000-0002-2133-9578
Abdelhay A AbdelhayDepartment of Diagnostic Radiology, Cairo University, Giza, Egypt.
Bahaa Eldin MahmoudDepartment of Diagnostic Radiology, Cairo University, Giza, Egypt.
Karima OuallaMedical Oncology Department, Hassan II University Hospital Sidi Mohamed Ben Abdellah University, Fes, Morocco.
Nesrine ChraietMedical Oncology Department, Salah Azaiez National Cancer Institute, Tunis, Tunisia.
Hussein AwadElkarim H MakiClinical Oncology Department, Ahfad University for Women, Khartoum, Sudan.
Yasser Abdel KaderClinical Oncology and Nuclear Medicine Department, Kasr Al-Aini Medical School, Cairo University, Cairo, Egypt.
Cairo University · EGAin Shams University · EGMansoura University · EGAlexandria University · EGAhfad University for Women · SDAssiut University · EGInstitut Salah-Azaïz · TNSidi Mohamed Ben Abdellah University · MASuez University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeColorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide and the second cause of cancer related mortality. Treatment options for patients with metastatic CRC (mCRC) expanded during the last two decades, with introduction of new chemotherapeutic and targeted agents. Egypt is a lower middle-income country; Egyptian health care system is fragmented with wide diversity in drug availability and reimbursement policies across different health care providing facilities. We report the results of consensus recommendations for treatment of patients with metastatic colorectal cancer developed by Egyptian Foundation of Medical Sciences (EFMS), aiming to harmonize clinical practice through structured expert consensus-based recommendations consistent with the national status. EFMS recommendations could be utilized in other countries with similar economic status.

methodsEFMS recommendations were developed using a modified Delphi process, with three rounds of voting till the final recommendations were approved. A non-systematic review of literature was conducted before generating the provisional statements. Content experts were asked to vote on some recommendations in two different resource groups (restricted resources and non-restricted resources). External review board of experts from a low income and lower-middle countries voted on the applicability of EFMS recommendations in their countries.

resultsThe current recommendations highlighted the discrepancy in health care between restricted and non-restricted resources with expected survival loss and quality of life deterioration. Access to targeted agents in first line is very limited in governmental institutions, and no access to agents approved for third line in patients who failed oxaliplatin and irinotecan containing regimens for patients treated in restricted resource settings.

conclusionManagement of mCRC in developing countries is a challenge. The currently available resource-stratified guidelines developed by international cancer societies represent a valuable decision-making tool, adaptation to national status in each country based on healthcare system status is required.

Indexed as

colorectal cancer CRCconsensus recommendationsmanagement in a lower-middle income countrymetastatic CRC

Identifiers

PMID35250310
PMCPMC8896768
OpenAlexW4214480099

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.